Fulcrum Therapeutics Securities Investigation
Analysis based on 26 articles · First reported Jul 15, 2026 · Last updated Aug 31, 2026
The investigation adds legal and reputational pressure on Fulcrum Therapeutics, potentially affecting its stock price and investor confidence. The discontinuation of its lead drug candidate and the subsequent securities investigation could impair the company's ability to raise capital and may lead to significant financial liabilities if the investigation results in a lawsuit or settlement.
Kaplan Fox & Kilsheimer is investigating potential securities law violations by Fulcrum Therapeutics, Inc. (Nasdaq: FULC). The investigation stems from Fulcrum's June 1, 2026 announcement that it was discontinuing its pociredir program for sickle cell disease (SCD) after the United States — Food and Drug Administration (FDA) expressed heightened concerns about the drug's benefit-risk profile. The FDA concluded that any pharmacological intervention targeting the PRC2 complex carries equivalent malignancy risk, citing an unexpectedly high rate of secondary hematologic malignancies observed with Tazverik (tazemetostat), another PRC2 inhibitor withdrawn from the global market in March 2026. Following the announcement, Fulcrum's stock price fell from $6.42 to $3.14 per share, a decline of 51.09%. Kaplan Fox is seeking investors who suffered losses to contact the firm.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard